BioCentury
ARTICLE | Strategy

Full set in hemophilia

How Pfizer’s Sangamo deal fits into its hemophilia and gene therapy strategies

Emily Cukier-Meisner, Senior Writer
May 19, 2017 10:55 PM UTC
BeneFIX sales peaked at $856 million and Xyntha at $631 million in 2014, the same year the first long-acting factor replacements reached the market. Pfizer reported 2016 revenues of $712 million for BeneFIX and $554 million for Xyntha.

Pfizer Inc.’s deal with Sangamo Therapeutics Inc. brings in what the pharma believes is the last of three mechanisms it needs to cover the hemophilia population with new non-factor replacement therapies.

The companies announced the worldwide license and collaboration agreement to develop and commercialize gene therapies for hemophilia A on May 10. Sangamo expects to begin a Phase I/II study of lead program SB-525 this month...

BCIQ Company Profiles

Pfizer Inc.

Sangamo Therapeutics Inc.

Spark Therapeutics Inc.